Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion – CNS tumours

3348 - Tumor mutational burden and immune infiltrates in primary renal cell carcinoma and matched brain metastases


28 Sep 2019


Poster Discussion – CNS tumours


Ariane Steindl


Annals of Oncology (2019) 30 (suppl_5): v143-v158. 10.1093/annonc/mdz243


A. Steindl1, E.S. Bergen1, D. Alpar2, B. Gatterbauer3, K. Dieckmann4, G. Widhalm3, J.A. Hainfellner5, M. Schmidinger1, C. Bock2, L. Müllauer6, M. Preusser1, A.S. Berghoff1

Author affiliations

  • 1 Department Of Medicine I, Medical University of Vienna, 1090 - Vienna/AT
  • 2 Cemm Research Center For Molecular Medicine, Austrian Academy of Sciences, 1090 - Vienna/AT
  • 3 Department Of Neurosurgery, Medical University of Vienna, 1090 - Vienna/AT
  • 4 Department Of Radiotherapy, Medical University of Vienna, 1090 - Vienna/AT
  • 5 Institute Of Neurology, Medical University of Vienna, 1090 - Vienna/AT
  • 6 Department Of Pathology, Medical University of Vienna, 1090 - Vienna/AT


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3348


High tumor mutational burden (TMB) as well as high density of tumor infiltrating lymphocytes (TIL) have been postulated as predictive response biomarkers for immune checkpoint inhibitor-based therapies. Therefore, we aimed to investigate the concordance of TMB and TIL in a series of primary/extracranial renal cell carcinoma specimens and matched brain metastases (BM).


Specimens from 10 patients with brain metastatic renal cell carcinoma were retrieved from the Vienna Brain Metastasis Registry (6/10 primary renal cell tumor, 4/10 lung metastasis, 10/10 matched BM). TMB was assessed using the TruSight Oncology 500 gene panel with libraries sequenced on a NextSeq instrument. TIL subsets (CD3+, CD8+) were investigated using the Ventana Benchmark Ultra system for immunohistochemistry and automated tissue analysis (Definiens software).Spearman correlation coefficient (SCC) and paired t-test were used to correlate and compare scale variables.


Median TMB was 5.4 mut/Mb (range 0-8.6 mut/Mb) in extracranial samples and 5.9 mut/Mb (range 3.1 – 59.6 mut/Mb) in BM (p > 0.05; paired t-test). Median density of CD3+ TIL in extracranial samples was 3.7/nm2 (range 4.9 – 7.1/nm2) and 5.2/nm2 (range 7.0 – 9.8/nm2) in BM (p > 0.05; paired t-test). Median density of CD8+ TIL was 3.2/nm2 (range 4.4 – 8.7/nm2) in extracranial samples and 3.7/nm2 (range 5.9 – 8.8/nm2) in BM (p > 0.05; paired t-test). No significant correlation of CD3+ TIL density and TMB (SCC: 0.02), CD8+ TIL density and TMB (SCC: 0.42) nor CD3+ and CD8+ TIL density (SCC: 0.18; p > 0.05) was observed in the present cohort.


TMB and TIL density were numerically higher in BM compared to the matched extracranial samples in the present cohort. Although results have to be interpreted with caution due to the limited sample size, our results support the further exploration of immune checkpoint inhibitors also in patients with BM from renal cell carcinoma.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


M. Preusser: Research grant / Funding (self): Böhringer-Ingelheim; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): GlaxoSmithKline; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Merck Sharp & Dome; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Roche; Honoraria (self), Advisory / Consultancy: Bristol-Myers Squibb; Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self), Advisory / Consultancy: Gerson Lehrman Group; Honoraria (self), Advisory / Consultancy: CMC Contrast; Honoraria (self), Advisory / Consultancy: Mundipharma; Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (self), Advisory / Consultancy: AbbVie; Honoraria (self), Advisory / Consultancy: Lilly; Honoraria (self), Advisory / Consultancy: Medahead; Honoraria (self), Advisory / Consultancy: Daiichi Sankyo. A.S. Berghoff: Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Daiichi Sankyo; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self), Travel / Accommodation / Expenses: Roche; Honoraria (self), Advisory / Consultancy: Bristol-Meyers Squibb; Honoraria (self), Advisory / Consultancy: Merck; Travel / Accommodation / Expenses: Amgen; Travel / Accommodation / Expenses: AbbVie. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.